Merck & Co., Inc.
MRK
USReal-Time PriceMerck & Co., Inc. (MRK) Stock News
The latest Merck & Co., Inc. (MRK) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Biotech Catalysts Put Moderna and Achieve Life Sciences in Focus
A dense clinical calendar gives investors several binary events, led by Moderna and Merck’s melanoma program and Achieve Life Sciences’ response to an FDA manufacturing rejection.
Moderna's 6% Rally Had No New Company Announcement Behind It
Moderna outpaced biotech peers during an October 15 healthcare rally. The stock's stronger move may reflect enthusiasm for its cancer-vaccine program, but fuller trial data remains the next fundamental test.
Moderna's 10% Drop Raises the Stakes for Its Melanoma Data
Moderna gave back part of its cancer-vaccine rally before a fuller melanoma presentation. The decline looks concentrated in the stock, but calling it profit-taking is an interpretation, not a confirmed cause.
Amgen and Merck Dividends Look Similar, but Coverage Does Not
Amgen and Merck offer nearly identical yields, yet normalized earnings and cash flow tell different stories. One-time charges make Merck's headline payout ratio misleading. for investors.
Moderna's Cancer-Vaccine Breakthrough Now Faces a Valuation Test
Moderna's Phase 3 melanoma success transformed the stock, but the treatment remains investigational and the company still loses money. Detailed efficacy, safety and regulatory timing now matter more than momentum.
Moderna's 600% Rally Shows What Clinical De-Risking Can Do
Moderna's stock has outpaced the biotech sector after its Phase 3 melanoma success. The move reflects a genuine change in clinical probability, while full data and commercialization still determine how much value remains.
The Case for Waiting on Moderna Is About Revenue, Not the Science
Moderna's oncology pipeline has been clinically de-risked, but current products still generate limited revenue relative to its valuation. The next earnings report must show that the commercial base is stabilizing.
Merck's Newer Medicines Are Growing, but Gardasil Still Matters
Merck's Winrevair and Capvaxive are expanding rapidly as Lipfendra joins the pipeline, yet Gardasil still generated $1.2 billion in the second quarter. Diversification is improving, not complete.
Vaxcyte’s VAX-31 Phase 3 Win Raises the Competitive Bar
VAX-31 met its pivotal adult immunogenicity goals, strengthening Vaxcyte’s case for broader pneumococcal coverage while execution risks remain.
Vaxcyte Phase 3 Data Strengthen VAX-31, but Two Trials Still Matter
VAX-31 met all prespecified OPUS-1 primary endpoints and broadened serotype coverage, supporting a best-in-class thesis while regulatory and manufacturing risk remain.
VAX-31 Creates a Longer-Term Competitive Risk for Pfizer Prevnar
Vaxcyte matched established pneumococcal vaccines across shared serotypes and added broader coverage, but Pfizer has time to defend Prevnar before a possible 2028 filing.
Moderna’s 8% Rally Had No Clear New Catalyst, Making Positioning the Bigger Story
Moderna rose sharply while biotech peers stayed quiet and no fresh company release clearly explained the move. The session looks more like momentum or positioning than a new clinical revaluation, keeping future trial milestones central to the thesis.
Healthcare ETF Flows Are Recovering After a Strong Biopharma Rally
J.P. Morgan sees healthcare ETF flows recovering after years of relative weakness, while large-cap biopharma has already outperformed. The setup could support further rotation, but fund flows alone are not enough to sustain the sector’s valuation gains.
A Congressional Merck Purchase Is Interesting Disclosure Data, Not an Investment Thesis
Rep. Maria Elvira Salazar disclosed Merck purchases valued in broad reporting ranges. The filing is useful transparency, but investors should avoid treating congressional trading data as a substitute for Merck’s pipeline, earnings and valuation.
Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up
Merck’s Phase 3 melanoma vaccine success strengthens its oncology growth case, but Keytruda’s patent cliff, valuation, pricing and tariff risks challenge whether future pipeline gains justify the current share price.
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)
Investors assess weaker futures, resilient economic data, higher Treasury yields, Iran tensions and sharp moves in Coty, Nordson, Webull, Moderna and Walmart as artificial intelligence and capital costs shape markets.